Exelixis, Inc. (EXEL)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $14.46B
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Latest financial period: July 3, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 3, 2026
Profit #81 of 1483 companies
| | Jul 26 | Apr 26 | Jan 26 | Oct 25 |
|---|
| ROE/ROA | 93.6% | 93.4% | 91.2% | 88.6% |
Growth #430 of 1483 companies
Payout #699 of 1483 companies
Safety #166 of 1483 companies
Price #262 of 1483 companies
